Allaxys Communications --- Transponder V --- Allaxys Forum 1

Advanced search  


24.2.2022 Rußland hat 3300 Panzer
. . . . . . . . .
11.11.2022 Rußland hat nur noch 486 Panzer
12.11.2022 Rußland hat nur noch 462 Panzer
13.11.2022 Rußland hat nur noch 460 Panzer
14.11.2022 Rußland hat nur noch 452 Panzer
15.11.2022 Rußland hat nur noch 439 Panzer
16.11.2022 Rußland hat nur noch 429 Panzer
17.11.2022 Rußland hat nur noch 422 Panzer
18.11.2022 Rußland hat nur noch 421 Panzer
19.11.2022 Rußland hat nur noch 415 Panzer
20.11.2022 Rußland hat nur noch 414 Panzer
21.11.2022 Rußland hat nur noch 408 Panzer
22.11.2022 Rußland hat nur noch 405 Panzer
23.11.2022 Rußland hat nur noch 403 Panzer
24.11.2022 Rußland hat nur noch 402 Panzer
25.11.2022 Rußland hat nur noch 401 Panzer
26.11.2022 Rußland hat nur noch .?.?.? Panzer

Pages: [1]

Author Topic: Do financial interests result in positive results in scientific research?  (Read 2213 times)


  • Jr. Member
  • *
  • Posts: 32

Pressemitteilung des British Medical Journal

Virtually all (94%) of the scientific authors who provided positive results for the anti-diabetic drug rosiglitazone had financial relationships with pharmaceutical companies, according to research published on today.

While the study acknowledges that financial relationships may not necessarily be the reason for positive research results, it concludes that further reform is needed to ensure trust in scientific work.

BMJ. 2010 Mar 18;340:c1344. doi: 10.1136/bmj.c1344.
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.

Wang AT, McCoy CP, Murad MH, Montori VM.

Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

OBJECTIVE: To explore a possible link between authors' financial conflicts of interest and their position on the association of rosiglitazone with increased risk of myocardial infarction in patients with diabetes. DATA SOURCES: On 10 April 2009, we searched Web of Science and Scopus for articles citing and commenting on either of two index publications that contributed key data to the controversy (a meta-analysis of small trials and a subsequent large trial). Data selection Articles had to comment on rosiglitazone and the risk of myocardial infarction. Guidelines, meta-analyses, reviews, clinical trials, letters, commentaries, and editorials were included. DATA EXTRACTION: For each article, we sought information about the authors' financial conflicts of interest in the report itself and elsewhere (that is, in all publications within two years of the original publication and online). Two reviewers blinded to the authors' financial relationships independently classified each article as presenting a favourable (that is, rosiglitazone does not increase the risk of myocardial infarction), neutral, or unfavourable view on the risk of myocardial infarction with rosiglitazone and on recommendations on the use of the drug. RESULTS: Of the 202 included articles, 108 (53%) had a conflict of interest statement. Ninety authors (45%) had financial conflicts of interest. Authors who had a favourable view of the risk of myocardial infarction with rosiglitazone were more likely to have financial conflicts of interest with manufacturers of antihyperglycaemic agents in general, and with rosiglitazone manufacturers in particular, than authors who had an unfavourable view (rate ratio 3.38, 95% CI 2.26 to 5.06 and 4.29, 2.63 to 7.02, respectively). There was likewise a strong association between favourable recommendations on the use of rosiglitazone and financial conflicts of interest (3.36, 1.94 to 5.83). These links persisted when articles rather than authors were used as the unit of analysis (4.69, 2.84 to 7.72), when the analysis was restricted to opinion articles (6.29, 2.15 to 18.38) or to articles in which the rosiglitazone controversy was the main focus (6.50, 2.56 to 16.53), and both in articles published before and after the Food and Drug Administration issued a safety warning for rosiglitazone (3.43, 0.99 to 11.82 and 4.95, 2.87 to 8.53, respectively). CONCLUSIONS: Disclosure rates for financial conflicts of interest were unexpectedly low, and there was a clear and strong link between the orientation of authors' expressed views on the rosiglitazone controversy and their financial conflicts of interest with pharmaceutical companies. Although these findings do not necessarily indicate a causal link between the position taken on the cardiac risk of rosiglitazone in patients with diabetes and the authors' financial conflicts of interest, they underscore the need for further changes in disclosure procedures in order for the scientific record to be trusted.

zum Volltext des frei verfügbaren Artikels:


  • Jr. Member
  • *
  • Posts: 32
Do financial interests result in positive results in scientific research?
« Reply #1 on: March 22, 2010, 06:13:11 AM »


Wie Pharma-PR in die Zeitung kommt: Ein Lehrstück

Beitrag von Autor hockeystick am 20.3.2010 in der "Stationären Aufnahme".

LESEN. Das ist wirklich ein Lehrstück par excellence ;-)))


  • Jr. Member
  • *
  • Posts: 38
Re: Do financial interests result in positive results in scientific research?
« Reply #2 on: December 25, 2021, 08:08:37 AM »

Marke: 2000
Pages: [1]